Carmichael Hill & Associates, Inc. Bio N Tech Se Transaction History
Carmichael Hill & Associates, Inc.
- $279 Million
- Q3 2024
A detailed history of Carmichael Hill & Associates, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Carmichael Hill & Associates, Inc. holds 10 shares of BNTX stock, worth $1,221. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10
Previous 10
-0.0%
Holding current value
$1,221
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding BNTX
# of Institutions
358Shares Held
38.4MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$1.01 Billion0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$552 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$532 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$231 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$221 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $29.6B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...